BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)

Trial Details

NCT ID
NCT05370430
Phase
PHASE1
Sponsor
PeproMene Bio, Inc.
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • BAFFR-CAR T cells
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Stanford, California, United States|37.42411,-122.16608
  • Kansas City, Kansas, United States|39.11417,-94.62746
  • Minneapolis, Minnesota, United States|44.97997,-93.26384
  • Charlotte, North Carolina, United States|35.22709,-80.84313

Key Eligibility Criteria

  • Informed Consent: Signed informed consent by the participant or legally authorized representative.
  • Age \& Performance Status:
  • Age ≥ 18 years
  • ECOG performance status ≤ 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →